References
- Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417–2429.
- Cicardi M, Aberer W, Banerji A, et al., Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy. 2014;69(5):602–616.
- Perego F, Wu MA, Valerieva A, et al. Current and emerging biologics for the treatment of hereditary angioedema. Expert Opin Biol Ther. 2019;19(6):517–526.
- Chen M, Riedl MA. Emerging therapies in hereditary angioedema. Immunol Allergy Clin North Am. 2017;37(3):585–595.
- Maurer M, Magerl M, Betschel S, et al., The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961–1990.
- Zanichelli A, Mansi M, Periti G, et al. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency. Expert Rev Clin Immunol. 2013;9(5):477–488.
- Drouet C, Désormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol. 2008;121(2):429–433.
- Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153–161.
- Wu MA, Zanichelli A, Mansi M, et al. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin Pharmacother. 2016;17(1):27–40.
- Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114(4):281–288.e7.
- EMA. Cinryze [Internet]. European Medicines Agency. 2018 cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze.
- EMA. Ruconest [Internet]. European Medicines Agency. 2018 cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest.
- Berinert - Polvere (Inibitore Della C1 Esterasi Umana) [Internet]. Codifa. cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.codifa.it/farmaci/b/berinert-inibitore-della-c1-esterasi-umana-antifibrinolitici-inibitori-delle-proteasi.
- Research C for BE and. HAEGARDA. FDA [Internet]. 2022 cited 2022 Feb 26]; Available from 2022 Feb 26: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/haegarda.
- EMA. Takhzyro [Internet]. European Medicines Agency. 2018 cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro.
- EMA. Orladeyo [Internet]. European Medicines Agency. 2021 cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo.
- Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140.
- Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793–1802.e2.
- Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–2121.
- Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study. Allergy. 2022;77(3):979–990.
- Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164–172.e9.
- Wedner HJ, Aygören-Pürsün E, Bernstein J, et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). J Allergy Clin Immunol Pract. 2021;9(6):2305–2314.e4.
- EMA. Firazyr [Internet]. European Medicines Agency. 2018 cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr.
- Kalbitor (ecallantide) FDA Approval History [Internet]. Drugs.com. cited 2022 Feb 26]. Available from 2022 Feb 26: https://www.drugs.com/history/kalbitor.html.
- Meini S, Zanichelli A, Sbrojavacca R, et al. Understanding the Pathophysiology of COVID-19: could the Contact System Be the Key? Front Immunol. 2020;11:2014.
- Pharma [Internet]. cited 2022 Feb 24]. Available from 2022 Feb 24: https://pharma.id.informa.com/signin?startURL=%2Fsetup%2Fsecur%2FRemoteAccessAuthorizationPage.apexp%3Fsource%3DCAAAAX8sROkJMDAwMDAwMDAwMDAwMDAwAAAA7BlHrFpqCXqC6mOU9EuIFDbF5ccALOhfWC_qTTa_1Pql7uH9AkyRMV7Dm_ZB-Ko1q9WCbc99q0yolFD86gU-wA8sRAjJMx2_cNPf4_u0O7tL-kc1yg_bpMIdExSX05rwA_e9u51U4dkKCzLScgaiWXXivm0xtfQXaysIllMhbBEJDrDY8lc7FcOks1GAYHBtUwGQrR8sYJAH8M5AmqR4Gr97eUuCCr5YsfsQ3EJ-t3F7pE9VIJvdGSJw8YlGr8E4if6KHD3eL-9Zp7Fj_-GPGxzgLF4xjjAo2gjAcd2k5X2lXhD1F2Dopz07ZJrqCLgWaNfJsUlgyrTe7vEk6SUj3wH1FLxtURY51fjURFRgEUzRvMsarL-IeDPagZLl7Gm-d7DA9oy6-d9s_7jyueclHH96C8iGS64KloqfS-NOlcpmE1UWbFwdKGY9hajdRj7oLb6xOgUcS92j0g9JjyVSKAJ7a_AX2DI71ptuucuacDIq0fsare3uC2rWtPEtGyWVfC1ocX1i0lZXHcLnHKqgwpv-zJo-M-IoiE0DIK8UbA_Qwc-9NDlOpC6i4JWas00BDF-6hvmWek-UGXA7Dy-G2wuZO0FFgrHVUlOe5-VKDqZPWfC_eI1Bt3k0b6YMEKmwYzylUsjsTSpDqV8Ba7pYc_Sctm0uE1ET28fYHT5wXNPB7IO0Efkunv4x_dz4-zzXIxDzU8N8PcxAvZ2e6d4Dle2vgcbcieOWalSmYY5M2bmufzSKMw74MhOL3jsnAGVmZ5D_6S8gtHlWUfLVmPmJ7X1uumudY4BiyU4scX7uMHusvWwTTMfMA42BdAjMXJcZJWUUnIJik4jx7zLwzawvamlsyahpP-bS2-TmhBmyW3eWrSEvHOftBhDyPWA48VFOZzaSWq8-uqIE0CXpgBWdWM8%253D.
- KalVista Pharmaceuticals, Ltd. A randomized, double-blind, placebo-controlled, phase 3, three-way crossover trial to evaluate the efficacy and safety of two dose levels of KVD900, an oral plasma kallikrein inhibitor, for on-demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema type I or II [Internet]. clinicaltrials.gov; 2022 [cited 2022 Mar 30]. Report No.: NCT05259917. Available from: https://clinicaltrials.gov/ct2/show/NCT05259917.
- Fijen LM, Riedl MA, Bordone L, et al. Inhibition of prekallikrein for hereditary angioedema. N Engl J Med. 2022;386(11):1026–1033.